Literature DB >> 15763641

Hormonal therapy of endometrial cancer.

Maurie Markman1.   

Abstract

Hormonal therapy of advanced or recurrent endometrial cancer is a well-established therapeutic option. Patients most likely to respond have lower grade tumours and possess progesterone receptors on the surface of their cancer cells.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15763641     DOI： 10.1016/j.ejca.2004.12.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  15 in total

1.  Characterization of LHY-821, a novel moderately differentiated endometrial carcinoma cell line.

Authors:  Qian Hu; Li Yu; Rui Chen; Yan Zhang; Ya Xie; Qinping Liao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

2.  Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.

Authors:  Erica M Stringer; Gini F Fleming
Journal:  Oncol Hematol Rev       Date:  2013

3.  Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy.

Authors:  Deanna M Janzen; Miguel A Rosales; Daniel Y Paik; Daniel S Lee; Daniel A Smith; Owen N Witte; M Luisa Iruela-Arispe; Sanaz Memarzadeh
Journal:  Cancer Res       Date:  2013-06-06       Impact factor: 12.701

Review 4.  Hormonal therapy in advanced or recurrent endometrial cancer.

Authors:  Fani Kokka; Elly Brockbank; David Oram; Chris Gallagher; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

5.  Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Authors:  Flora Zagouri; George Bozas; Eftichia Kafantari; Marinos Tsiatas; Nikitas Nikitas; Meletios-A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2010-02-02

Review 6.  Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.

Authors:  Erica M Stringer; Gini F Fleming
Journal:  Eur Endocrinol       Date:  2013-03-15

Review 7.  PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.

Authors:  Felicia Roncolato; Kristina Lindemann; Melina L Willson; Julie Martyn; Linda Mileshkin
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07

8.  Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.

Authors:  Yongli Chu; Yanlin Wang; Guanghua Zhang; Haibin Chen; Sean C Dowdy; Yuning Xiong; Fengming Liu; Run Zhang; Jinping Li; Shi-Wen Jiang
Journal:  Cell Mol Life Sci       Date:  2014-02-15       Impact factor: 9.261

Review 9.  Role of progesterone in endometrial cancer.

Authors:  J Julie Kim; Eloise Chapman-Davis
Journal:  Semin Reprod Med       Date:  2010-01-26       Impact factor: 1.303

Review 10.  Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

Authors:  Stephanie Lheureux; Carolyn McCourt; B J Rimel; Linda Duska; Gini Fleming; Helen Mackay; David Mutch; Sarah M Temkin; Jean Lynn; Elise C Kohn
Journal:  Gynecol Oncol       Date:  2018-02-22       Impact factor: 5.304
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.